1. Home
  2. CRGX vs SPE Comparison

CRGX vs SPE Comparison

Compare CRGX & SPE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRGX
  • SPE
  • Stock Information
  • Founded
  • CRGX 2021
  • SPE 1993
  • Country
  • CRGX United States
  • SPE United States
  • Employees
  • CRGX N/A
  • SPE N/A
  • Industry
  • CRGX
  • SPE Finance/Investors Services
  • Sector
  • CRGX
  • SPE Finance
  • Exchange
  • CRGX Nasdaq
  • SPE Nasdaq
  • Market Cap
  • CRGX 180.4M
  • SPE 162.3M
  • IPO Year
  • CRGX 2023
  • SPE N/A
  • Fundamental
  • Price
  • CRGX $4.07
  • SPE $15.03
  • Analyst Decision
  • CRGX Hold
  • SPE
  • Analyst Count
  • CRGX 7
  • SPE 0
  • Target Price
  • CRGX $4.67
  • SPE N/A
  • AVG Volume (30 Days)
  • CRGX 773.9K
  • SPE 25.4K
  • Earning Date
  • CRGX 03-12-2025
  • SPE 01-01-0001
  • Dividend Yield
  • CRGX N/A
  • SPE 8.55%
  • EPS Growth
  • CRGX N/A
  • SPE N/A
  • EPS
  • CRGX N/A
  • SPE N/A
  • Revenue
  • CRGX N/A
  • SPE N/A
  • Revenue This Year
  • CRGX $119.08
  • SPE N/A
  • Revenue Next Year
  • CRGX N/A
  • SPE N/A
  • P/E Ratio
  • CRGX N/A
  • SPE N/A
  • Revenue Growth
  • CRGX N/A
  • SPE N/A
  • 52 Week Low
  • CRGX $3.00
  • SPE $10.26
  • 52 Week High
  • CRGX $25.45
  • SPE $12.59
  • Technical
  • Relative Strength Index (RSI)
  • CRGX 40.37
  • SPE 44.07
  • Support Level
  • CRGX $3.98
  • SPE $14.84
  • Resistance Level
  • CRGX $4.25
  • SPE $15.31
  • Average True Range (ATR)
  • CRGX 0.22
  • SPE 0.21
  • MACD
  • CRGX 0.16
  • SPE 0.01
  • Stochastic Oscillator
  • CRGX 36.84
  • SPE 44.26

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

About SPE Special Opportunities Fund Inc

Special Opportunities Fund Inc is the United States based closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds. In addition, it also makes investments in construction materials, consumer finance, healthcare equipment and supplies, independent power and renewable electricity producers, insurance, personal products, professional services and real estate investment trusts.

Share on Social Networks: